Key Points
- ICU Medical VP Virginia Ruth Sanzone sold 2,447 shares on May 14 at an average price of $124.08, totaling $303,623.76. After the sale, she still held 19,460 shares, reducing her ownership by 11.17%.
- The stock was trading lower, opening Friday at $118.72 and down 3.5% from the prior session. ICU Medical’s shares have ranged between $107.00 and $160.29 over the past 52 weeks.
- ICU Medical beat quarterly expectations on May 7, reporting EPS of $1.97 versus the $1.78 consensus and revenue of $525.77 million versus estimates of $520.65 million. The company also issued FY 2026 EPS guidance of $7.75 to $8.45.
ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
ICU Medical Trading Down 3.5%
Shares of ICUI stock opened at $118.72 on Friday. The stock has a market cap of $2.97 billion, a price-to-earnings ratio of 64.17, a price-to-earnings-growth ratio of 1.77 and a beta of 0.74. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $160.29. The firm's 50 day moving average price is $125.92 and its two-hundred day moving average price is $138.30.
ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating analysts' consensus estimates of $1.78 by $0.19. The firm had revenue of $525.77 million for the quarter, compared to analysts' expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. ICU Medical's revenue was down 12.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, analysts anticipate that ICU Medical, Inc. will post 6.31 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on ICUI. Weiss Ratings raised shares of ICU Medical from a "sell (d)" rating to a "sell (d+)" rating in a research report on Monday. Jefferies Financial Group raised shares of ICU Medical to a "strong-buy" rating in a research report on Thursday, May 7th. Piper Sandler reduced their target price on shares of ICU Medical from $178.00 to $163.00 and set an "overweight" rating on the stock in a research report on Friday, April 17th. Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Finally, KeyCorp reduced their target price on shares of ICU Medical from $180.00 to $164.00 and set an "overweight" rating on the stock in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $169.00.
Get Our Latest Stock Report on ICUI
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of ICU Medical by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier's stock worth $387,313,000 after purchasing an additional 89,755 shares in the last quarter. Janus Henderson Group PLC raised its holdings in ICU Medical by 4.2% in the fourth quarter. Janus Henderson Group PLC now owns 2,576,756 shares of the medical instruments supplier's stock valued at $367,625,000 after acquiring an additional 103,220 shares in the last quarter. Millennium Management LLC raised its holdings in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock valued at $130,638,000 after acquiring an additional 690,694 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in ICU Medical by 6.8% in the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier's stock valued at $127,053,000 after acquiring an additional 63,026 shares in the last quarter. Finally, State Street Corp raised its holdings in ICU Medical by 2.8% in the fourth quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier's stock valued at $134,491,000 after acquiring an additional 25,545 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.
ICU Medical Company Profile
(
Get Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
